Randomized Phase II Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes.

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04802161

Study #:
STUDY00150895

Start Date:
Feb 20, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04802161

View Complete Trial Details & Eligibility at ClinicalTrials.gov